Company profile for QUESTCOR PHARMACEUTICALS INC

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus eryt...
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus erythematosus and systemic dermatomyositis; and as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Its H.P. Acthar Gel is also used for the treatment of acute exacerbations of multiple sclerosis in adults; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company sells its product primarily to specialty pharmacies. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California. As of August 14, 2014, Questcor Pharmaceuticals, Inc. was acquired by Mallinckrodt public limited company.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1300 North Kellogg Drive Suite D Anaheim, CA 92807
Telephone
Telephone
+1 714-786-4200
Client Website
Website
--
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/mallinckrodt-investors-stream-for-exits-as-opioid-tied-bankruptcy-talk-mounts

K. Blankenship FIERCEPHARMA
07 Sep 2019

https://www.fiercepharma.com/pharma/mallinckrodt-hit-new-kickback-charges-one-day-after-15-5m-settlement-feds

K. Blankenship FIERCE PHARMA
07 Jun 2019

https://www.reuters.com/article/us-mallinckrodt-doj/mallinckrodt-to-settle-u-s-drug-marketing-probe-fight-kickback-case-idUSKCN1T6263

Nate Raymond REUTERS
05 Jun 2019

https://www.reuters.com/article/us-mallinckrodt-lawsuit/mallinckrodt-shares-drop-after-u-s-joins-cases-over-expensive-drug-idUSKCN1S623P?feedType=RSS&feedName=healthNews

Nate Raymond REUTERS
02 May 2019

https://edition.cnn.com/2018/06/29/health/acthar-mallinckrodt-medicare-claims-doctor-payments/index.html

Wayne Drash CNN
02 Jul 2018
Mallinckrodt pays $1.2bn for Sucampo Pharma
Mallinckrodt pays $1.2bn for Sucampo Pharma

03 Jan 2018

// Phil Taylor PMLIVE

http://www.pmlive.com/pharma_news/mallinckrodt_pays_$1.2bn_for_sucampo_pharma_1215000

Phil Taylor PMLIVE
03 Jan 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty